Turnaround!
KI Aktie mit geheimer Super-Power?!
Anzeige
INOVIO PHARMACEUTICALS Forum: Community User: gerry
Kommentare 16.713
haras,
10.08.2020 22:06 Uhr
0
Warum sackt der Kurs Nachbörslich total ab???
S
SirDynamite,
10.08.2020 22:06 Uhr
0
Versteh das nicht. Shit
P
Phil1984,
10.08.2020 22:06 Uhr
0
Naja wird schon 😜
Q_mar,
10.08.2020 22:06 Uhr
0
Gute Zahlen, eigentlich... jetzt wird manipuliert
P
Phil1984,
10.08.2020 22:06 Uhr
0
Jetzt gehts richtig runter 🙈
D
DerMito,
10.08.2020 22:05 Uhr
0
Jetzt - 9 % 18,40$
Mihael,
10.08.2020 22:04 Uhr
0
Mein Link funktioniert auch nicht😏
FAC,
10.08.2020 22:04 Uhr
0
On June 3, 2020, we filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science,
Inc., collectively referred to as VGXI, alleging that VGXI had materially breached our supply agreement with them. The complaint seeks declaratory judgments,
specific performance of the agreement, injunctive relief, an accounting, damages, attorneys’ fees, interest, costs and other relief from VGXI. On June 3, 2020, we
filed a petition for preliminary injunction, which was denied on June 25, 2020. On June 26, 2020, we filed notice of appeal of the denial of the petition with the
Pennsylvania Superior Court.
On July 7, 2020, VGXI filed an answer, new matter and counterclaims against us, alleging that we had breached the supply agreement, as well as
misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys’ fees, interest, costs and other relief from us.
Also, on July 7, 2020, VGXI filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that we had engaged to provide
services similar to those that were being provided by VGXI. On July 27, 2020, we filed an answer to VGXI’s counterclaims, disputing the allegations and the
claims raised in VGXI’s filing. A trial date for the litigation has not been set.
We intend to aggressively prosecute the claims set forth in our complaint against VGXI and to vigorously defend ourselves against VGXI’s counterclaims.
Mihael,
10.08.2020 22:04 Uhr
0
Kann sich Longie durchlesen der versteht das😉😂😂
Mihael,
10.08.2020 22:03 Uhr
0
http://d18rn0p25nwr6d.cloudfront.net/CIK-0001055726/952770fd-3b6b-47c0-b357-0bed3f628b83.pdf
Mihael,
10.08.2020 22:02 Uhr
0
Super, muss mir das erstmal auf Deutsch übersetzen muss ich morgen wohl krank machen das ich alles lesen kann 🤣🤣🤣
FAC,
10.08.2020 22:02 Uhr
0
Gute Nacht Lektüre 😉
Mihael,
10.08.2020 22:01 Uhr
0
Sind ja nur 122 Seiten 😳😳
Mihael,
10.08.2020 22:01 Uhr
0
Ok ist doch da
FAC,
10.08.2020 22:01 Uhr
0
We have also initiated clinical trials of INO-4800 in South Korea and China. In April, CEPI awarded us a grant of $6.9 million to work with International
Vaccine Institute and the Korea National Institute of Health to conduct a Phase 1/2 trial, which is the first COVID-19 vaccine clinical trial approved in South
Korea. In China, we are collaborating with Beijing Advaccine Biotechnology Co. to conduct a Phase 1 trial, the initiation of which was approved by regulatory
authorities in July.
In parallel with our accelerated clinical development efforts, we have engaged a network of partners for the planned large-scale manufacturing of INO-4800
if it achieves regulatory approval. In March, the U.S. Department of Defense, or DoD, awarded Ology Bioservices Inc. a contract to manufacture INO-4800 for the
DoD to be used in upcoming clinical trials. In April, we entered into an agreement with the German contract manufacturer Richter-Helm BioLogics GmbH & Co.
KG and expanded our preexisting manufacturing partnership to support large-scale manufacturing of INO-4800. In March, we also received a grant from the Bill
and Melinda Gates Foundation for accelerated testing and scale up of our CELLECTRA 3PSP proprietary smart device for the intradermal delivery of INO-4800.
In June, the DoD awarded us $71 million to support the large-scale manufacture of CELLECTRA 3PSP and the procurement of CELLECTRA 2000 devices that
are used to deliver INO-4800 intradermally.
With this growing coalition of partners and funders, and with our existing capacity and current and planned contract resources, we are seeking to produce up
to one million doses of INO-4800 by the end of 2020 and 100 million doses in 2021.
Mihael,
10.08.2020 22:00 Uhr
0
Bis jetzt noch keine Mail bekommen 🤨🤔🤔
Meistdiskutiert
|
|
Thema | ||
|---|---|---|---|
| 1 | Germany 40 / DAX Prognose | +0,53 % | |
| 2 | SERVICENOW Hauptdiskussion | -3,58 % | |
| 3 | Germany 40 Hauptdiskussion | +0,53 % | |
| 4 | LUFTHANSA Hauptdiskussion | -11,25 % | |
| 5 | DPCM Capital Hauptdiskussion | +3,20 % | |
| 6 | HauptForum SK HYNIC | +3,93 % | |
| 7 | BAYER Hauptdiskussion | +3,93 % | |
| 8 | Palantir ohne Schnickschnack | +11,79 % | |
| 9 | INTEL Hauptdiskussion | +5,55 % | |
| 10 | ZALANDO Hauptdiskussion | -14,62 % | Alle Diskussionen |
Aktien
|
|
Thema | ||
|---|---|---|---|
| 1 | SERVICENOW Hauptdiskussion | -2,90 % | |
| 2 | LUFTHANSA Hauptdiskussion | -11,25 % | |
| 3 | DPCM Capital Hauptdiskussion | +3,67 % | |
| 4 | HauptForum SK HYNIC | +3,82 % | |
| 5 | BAYER Hauptdiskussion | +4,01 % | |
| 6 | Palantir ohne Schnickschnack | +14,66 % | |
| 7 | INTEL Hauptdiskussion | +5,60 % | |
| 8 | ZALANDO Hauptdiskussion | -14,80 % | |
| 9 | Ecograf - ein Stern am Graphithimmel | +3,42 % | |
| 10 | MCDONALDS Hauptdiskussion | +0,82 % | Alle Diskussionen |